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Abstract. Basic fibroblast growth factor (bFGF) is a
potent mitogen for human bone marrow stromal cells
and stimulates haematopoiesis in vitro. We report here
that primary human bone marrow cultures contain
bFGF and express heparin-like bFGF binding sites on
the cell surface and in the extracellular matrix (ECM).
bFGF bound predominantly to a 200-kD cell surface
heparan sulfate proteoglycan (HSPG), which was also
found in conditioned medium.
bFGF was released from bone marrow cultures by
incubation with phosphatidylinositol-specific phospho-
lipase C (PI-PLC) and, less efficiently, by plasmin.
Solubilized bFGF was found as a complex with the
20041) HSPG. The complex was biologically active
as shown by its ability to stimulate plasminogen acti-
vator production in bovine aortic endothelial cells.
bFGF-HSPG complexes of bovine endothelial cells,
P
ROLIFERATION and differentiation of haematopoietic
stemcells in bone marrow is dependentonthecontin-
uoussupply ofgrowth factors suchasthecolony stim-
ulatingfactors(Metcalf, 1986;ClarkandKamen, 1987), and
close associationbetween theprimitive progenitor cells and
bone marrow stromal cells is required (Dexter et al., 1977;
Dexter, 1982). Itisthoughtthatstromalcells producegrowth
factors essential for haematopoietic cell development and
that these are deposited in the extracellular matrix (ECM)1.
Thefactthatgranulocyte-macrophage colony stimulatingfac-
torand interleukin-3 have been shown to bind in a biologi-
cally active form to heparan sulfate in bone marrow stroma
(Gordon et al., 1987; Roberts et al., 1988) supports this
hypothesis.
Basic fibroblast growth factor (bFGF), a ubiquitous mul-
1. Abbreviations used in this paper: BAE, bovine aortic endothelial; BCE,
bovine capillary endothelial; bFGF, basic fibroblast growth factor; ECM,
extracellular matrix; HSPG, heparan sulfate proteoglycan; KIU, Kallikrein
inhibitor unit; PA, plasminogen activator; PI, phosphatidylinositol; PLC,
phospholipase C.
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however, were not released by PI-PLC.
While only traceamounts ofthe bFGF-binding 200-kD
HSPG were released spontaneously from bone marrow
cultures, incubation with PI-PLC solubilized almost
all of the 200-kD HSPG. The HSPG could be meta-
bolically labeled with ethanolamine orpalmitate, which
was partially removed by treatment with PI-PLC. These
findings indicate linkage of the HSPG to the cell sur-
face via a phosphatidylinositol anchor. Plasmin released
the 200-kD HSPG less efficiently than PI-PLC.
We conclude that HSPGs of human bone marrow
serve as a reservoir for bFGF, from which it can be
released in a biologically active form via a dual mech-
anism; one involving a putative endogenous phospholi-
pase, the other involving the proteolytic cascade of
plasminogen activation.
tifunctional growth factor, is foundinmany tissues, tumors,
andcell lines (for areview see Rifkin andMoscatelli, 1989).
In endothelial cells in vitro, bFGF acts as an autocrine
growth factor (Sato and Rifkin, 1988) and induces cell
growth, cellmigration, DNA synthesis, plasminogenactiva-
tor (PA), and metalloproteinase production, indicating the
involvement ofthis growth factor in neovascularization and
wound repair (Rifkin and Moscatelli, 1989). In humanbone
marrow cultures, bFGF stimulates cell growth and the for-
mation ofaprimary stromal cell layerand delays senescence
ofstromalcultures (Oliveretal., 1990). Italsoenhances my-
elopoiesis when added to long-term human bone marrow
cultures in vitro (Wilsonetal., 1991). Whereas bFGF alone
had no effect on colony formation by progenitor cells, it en-
hanced synergisticallythe frequencyofcoloniesproducedby
other haematopoietic growth factors (Gabbianelli et al.,
1990; Wilson et al., 1991).
bFGF is not found in significantamounts in serumorcell
culture supernatants (Gauthieretal., 1987) but is deposited
into the ECM ofendothelial cells (Vlodavsky et al., 1987).ECM-bound bFGF provides a reservoir of biologically
active growth factor, which is able to mediate long-term
biological effects (Flaumenhaft et al ., 1989). Nonreceptor
bFGF binding sites, heparan sulfate proteoglycans (HSPGs),
are present on the cell surface as well as in the ECM . The
growth factor is released from these sites as a biologically
active growth factor-heparan sulfate proteoglycan (HSPG)
complex by the serine proteinase plasmin (Saksela and Rif-
kin, 1990)and by heparanases (Ishai-Michaeli et al., 1990).
HSPGs are also modulators of the biological activity of
bFGF as heparin and heparan sulfate protect the growth fac-
tor from proteolytic inactivation (Saksela et al., 1988) . Poly-
anionic glycosaminoglycans also increase the diffusion of
bFGF within an endothelial cell monolayer, thereby extend-
ing the range of biological action ofthis factor (Flaumenhaft
et al., 1990). In addition, heparin-like molecules were
reported to be accessory molecules necessary for bFGF
binding to its high-affinity receptor (Yayon et al., 1991) . This
indicates thatbFGF complexes with HSPGs or glycosamino-
glycans serve as the biologically active forms of this growth
factor.
In this paper, we demonstrate that bFGF binds to HSPGs
of humanprimary bone marrow cultures. The major bFGF-
binding HSPG, which has a molecular size of -200 W, is
linked to the stromal cell surface via a phosphatidylinositol
(PI) anchor. Consequently, bFGF is released as biologically
active growth factor-HSPG complex not only by plasmin,
but more efficiently by PI-specific phospholipase C (PI-
PLC). These results suggest a dual mechanism of bFGF re-
lease in human bone marrow cultures. The first and more
efficient mechanism involves the release of PI-linked bFGF-
HSPG complexes from the stromal cell surface by a putative
endogenous phospholipase. The second mechanism involves
the proteolytic cascade of plasminogen activation and plas-
min-mediated ECM degradation also leading to the solubili-
zation of bFGF-HSPG complexes.
Materials andMethods
Reagents
Recombinant bFGF was a generous gift of Synergen Inc. (Boulder, CO)
(Sommer et al., 1987). [1111]bFGF (7.9 mCi/mg) was kindly provided by
Dr. D. Moscatelli (NYU Medical Center, New York). Sodium 05S]sulfate
(250-1,000 mCi/mmol) was obtained from Du Pont (Wilmington, DE), [1-
3H]ethanolamine (30.4 Ci/mmol) and [9,10(n)3H]palmitic acid (53.6
Ci/mmol) from Amersham (Arlington Heights, MA). PI-PLC (600 u/mg;
protease-free) and phosphatidylcholine PLC (PC-PLC; 2,000,u/mg) were
purchased from Boehringer (Mannheim, FRG). Plasminogen was purified
from outdated human plasma (Deutsch and Mertz, 1970), and urokinase-
type PA was purchased from Leo Pharmaceuticals (Denmark). Affinity-
purified polyclonal antibodies against recombinant bFGF (Dennis and Rif-
kin, 1990) were a generous giftofP. A. Dennis (NYUMedical Center, New
York). Goat anti-rabbit IgG coupled to alkaline phosphatase was obtained
from Promega Biotec (Madison, WI). Plasmin (4 It/mg), its chromogenic
substrate D-Val-Leu-Lys p-nitroanilide, heparinase (12,000 p/mg), aproti-
nin(9,900 KIU/mg), fatty-acid freeBSA, 4-methylumberylliferyl R-D-xylo-
side, hydrocortisone, heparin, 5-bromo-4-chloro-3-indolyl phosphate, nitro
blue tetrazolium, and protein A-Sepharose CL-4B were obtained from
Sigma Chemical Co. (St. Louis, MO).
CellCulture
Human bone marrow cells were obtained from healthy adult volunteers fol-
lowing informed consent. Buffy coat cells were seeded in alpha modified
Eagles medium (Flow Laboratories, McClean, VA) containing 12.5% FCS
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(Intergen Company, New York, NY), 12.5 % horse serum (Gibco Laborato-
ries, Grand Island, NY), 10- 6 M hydrocortisone, 10-° M 2-mercapto-
ethanol, 2 mM L-glutamine, andantibiotics. After3-4 wk an adherent stro-
mal cell layer containing haematopoietic progenitor cells was present
(Dexter, 1982). All experiments were performed using confluent cell layers
ofthe same frozen stockofprimarybonemarrow cells. For studieson bFGF
binding or on the enzymatic release of bFGF or HSPG into the medium,
the cultures were washed with PBS and incubated in the medium specified
above but without serum. Cell lysates were prepared by incubating the cell
layer withPBS containing 0.5 % Triton X-100 for 15 min at37°C. The resid-
ual stromal cell matrix, still containing fragments of the lysed cells, was
extracted for 15 min at 37°C with reducing SDS-PAGE sample buffer. This
extract represented a mixture ofcellular and matrix constituents because of
the incomplete separation of these components.
Bovine aortic (RAE) and capillary endothelial (BCE) cells were isolated
as described previously (Folkman et al., 1979) and grown at 37°C in alpha
modified Eagles medium supplemented with 5% calf serum, 2 mM L-glu-
tamine, and antibiotics. Cells were used for experiments between passage
5 and 10.
MetabolicLabelingofBone Marrow Cells
For the labeling of the glycosaminoglycan side chains of proteoglycans,
cells were grown until confluent in 24-well Linbro plates and incubated
overnight with ["S]sulfate (40 ACi/ml) in serum-free bone marrow culture
medium (250 ul/well).
For the labeling of the PI anchor of the 200-kD HSPG, 5 mCi of
[3H]palmitic acid weredried undernitrogen and dissolvedin 100 pl ofcold
95% ethanol. A palmitate-BSA complex was prepared by adding 1.25 ml
of a solution of20 mg/ml offatty-acidfreeBSAin 10 mM sodium phosphate
buffer, pH 7.0, containing 150 mM sodium chloride to the [3H]palmitic
acid. The complex was allowed to form for 1 h at room temperature. Cells
were grown until confluent in an 80-cmz flask and were incubated over-
night with the palmitate-BSA complex (0.8 mCi/ml) in serum-free bone
marrow culture medium (6.25 ml/flask) containing 200 KIU/ml aprotinin.
Alternatively, cells were incubated overnight with [3H]ethanolamine (167
pCi/ml) in serum-free medium containing 200 KIU/ml of aprotinin and 20
ng/ml of bFGF to achieve maximal incorporation of the label into the
HSPG. Cell lysates were prepared as described above and PMSF was added
to a final concentration of 1 mM.
1ZSIJbFGFBindingAssay
The [121I]bFGF binding assay was a modification of the procedure de-
scribed by Moscatelli andDevesly (1990). Bone marrow cells were cultured
in 96-well plates until confluent and incubated with 0-1,000 ng/ml of bFGF
containing 7.9-79 nCi/ml [125I]bFGF (7.9 mCi/mg) in serum-free bone
marrow cell culture medium (100Wl/well) supplemented with 0.15% gelatin
and 25 mM Hepes buffer, pH 7.2. After incubation on a shaker for 2 h at
4°C, excess bFGF was removed by extensive washing ofthe cell layers with
PBS followed by determination of theamount of radioactivity in the cell ex-
tract and the ECM, respectively, using a Packard MULTI-PRIAS 1 gamma
counter.
ImmunoprecipitationofbFGF-HSPG Complexes
HSPGs were metabolically labeled overnight with [35S]sulfate, [3H]pal-
mitic acid, or [3H]ethanolamine as described above. The labeled HSPGs
were precipitated by addition of bFGF-anti-bFGF IgG complexes immobi-
lized on protein A-Sepharose beads (Saksela and Rifkin, 1990). The pre-
cipitates were analyzed by SDS-PAGE (Laemmli, 1970) in 3-16% acryl-
amide gradient gels (Saksela and Rifkin, 1990).
bFGFLigand BindingAssay
Serum-free culture supernatants, cell lysates, and ECM extracts ofprimary
bone marrow cell cultures were subjected to SDS-PAGE in 3-16% acryl-
amide gradient gels. Proteins were transferred onto nitrocellulose filters
(Schleicher & Schuell, Keene, NH) according to 'Ibwbin et al. (1979) at
250-500 mA for 12-36 h. Unoccupied protein binding sites on the nitrocel-
lulose filters were blocked with 5% dry milk in PBS for 1 h. After incuba-
tion with bFGF (1 kg/ml in PBS containing 5 % dry milk) for 1 h, bound
bFGF was detected by incubation with affinity-purified rabbit anti-bFGF
IgG (5 /ig/ml in PBS containing 5 % dry milk) and goatanti-rabbit IgG cou-
pled to alkaline phosphatase (1:10,000 in PBS containing 5% dry milk).
1276Alkaline phosphatase activity was visualized using 5-bromo-4-chloro-3-
indolyl phosphate and nitro blue tetrazolium. All incubations were per-
formed at room temperature .
bFGF Immunoblotting
Immunoblotting was performed essentially as described for the bFGF
ligand binding assay (see above) except that the incubation step with bFGF
was omitted .
PAAssay
PA was assayed via the activation of plasminogen to plasmin followed by
the cleavage of a chromogenic plasmin substrate as described previously
(Brunner et al ., 1989) . BAE cells were cultured in 96-well plates until
confluent and incubated overnight with bFGF-containing samples . Cells
were then lysed by addition of 30mM Tris-HCI buffer, pH 7.5, containing
60 mM sodium chloride and 0.5% Triton X-100 (60 k1/well) . After incuba-
tion for 15 min at 37°C, PA activity in the cell lysates was determined
directly in the wells in a coupled chromogenic assay by adding 20 td of hu-
man plasminogen (500 hg/ntl) and 20 pl ofDVal-Leu-Lys p-nitroanilide
(3.5 mM) as substrates . After incubation for30 min at 37°C, optical density
at 405 nun was determined using a microtiter plate reader. The values were
corrected forplasmin contamination of the reagents (buffer control) and for
plasmin-independent turnover of the chromogenic substrate (controls lack-
ing plasminogen) .
Results
Demonstration ofEndogenous bFGF
inBone Marrow Cultures
It is known thatbFGF is a potent mitogen for primaryhuman
bonemarrow cells (Oliver et al., 1990) and that this growth
factor promotes myelopoiesis in long-term human bone mar-
row cultures (Wilson et al ., 1991) . To investigate whether
bFGF might be produced as an autocrine growth factor
by bone marrow cultures themselves, we examined Triton
X-100 cell lysates and ECM extracts for the presence of
bFGF immunoreactivity. In immunoblotting experiments
bFGF was found inECM extracts at a molecular weightposi-
tion of 18 kD (Fig . 1, lane 2), but was undetectable in cell
lysates (Fig . 1, lane 1) . A less intense band was also observed
at-32kD. This may represent a dimer ofbFGF (our unpub-
and anti-rabbit IgG coupled
Normal rabbit IgG (5 pg/ml)
were evident (not shown) .
Figure 1. Demonstration of
bFGF inprimary human bone
marrow cultures. Cells were cul-
tured until confluent and lysed
for 15 min at 37°C in PBS con-
taining 0.5% Triton X-100 (5
x 106 cells/ml) . The residual
stromal cell matrix was ex-
tractedfor 15 min at 37°C with
a corresponding volume of re-
ducing SDS-PAGE samplebuf-
fer. Aliquots of cell lysates
(lane 1) and ECM extracts
(lane 2) (each corresponding
to 4.5 x 105 cells) were ana-
lyzed by SDS-PAGE in 15
gelsunder reducing conditions.
bFGF was detected by immu-
noblotting using affinity-puri-
fied anti-bFGF IgG (5 p,g/ml)
to alkaline phosphatase (1:10,000) .
was used as a control and no bands
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Figure 2 . Identification of
bFGF-bindingHSPGs in bone
marrow cultures. Cells were
cultured in serum-containing
medium in 24-well plates until
confluent and extracted (250
Al/well) as described in Fig.
1 . Aliquots (90 Al) of cell
extracts, ECM, or 24-h se-
rum-free conditioned medium
(2501al/well) were analyzedby
SDS-PAGE in 3-16% gel gra-
dients under reducing condi-
tions . bFGF-binding molecules
were detected by ligand blot-
ting using recombinant bFGF
(1 pg/ml), affinity-purified anti-bFGF IgG (5 p,g/ml), and anti-
rabbit IgG coupled to alkaline phosphatase (1:10,000) . No bands
were seen using normal rabbit IgG as a control, or ifthe incubation
step with bFGF was omitted (not shown) . (lane 1) Conditioned
medium ; (lane 2) cell extract ; (lane 3) ECM extract .
lished data) . Since bFGF is not present in serum, this result
suggested thatbFGF was produced by the bonemarrow cul-
tures .
Identification ofHeparin-likebFGFBindingSites
inBoneMarrow Cultures
To demonstrate the presence of bFGF binding sites in pri-
mary human bone marrow cultures, exogenous [ 12Sí]bFGF
was added to confluent cell layers and cell-bound bFGF was
quantified in Triton X-100 cell lysates . The residual ECM
was then extracted with reducing SDS-PAGE sample buffer.
This extract represented a mixture of matrix and cellular
components, since the detergent treatment did not result in
complete removal of cells sequestered in the ECM .
Both compartments, bonemarrow cellsand theECM, con-
tained bFGF binding sites, which were not saturable up to
a bFGF concentration of 1 Ag/ml (results not shown) . After
addition ofbFGF, -13% of the growth factor was recovered
in the cell lysate and 27% in the ECM extract (i.e., a total
of 40%) . The bFGF binding capacity of bone marrow cul-
tures calculated from these values exceeded 70 ng/105 cells .
bFGF has been shown to bind to heparan sulfate and
HSPGs ofendothelial cells (Saksela et al ., 1988 ; Saksela and
Rifkin, 1990), and bFGF binding to these sites can be com-
peted by heparin (Flaumenhaft et al ., 1989) . We therefore
examined our bonemarrow cultures for evidence of heparin-
like bFGF binding sites, and noted that in the presence of
100 Ag/ml ofheparin, bFGF binding was almost completely
abrogated (results not shown) . More than 95% ofthe cellular
and98% ofthe matrixbinding sites were competableby hepa-
rin . This is consistent with previous reports onbFGF bind-
ing to cultures of BCE cells (Moscatelli, 1987, 1988) .
To characterize further the heparin-like bFGF binding
sites in primary bone marrow cultures, we prepared serum-
free conditioned medium, Triton X-100 cell lysates, and an
extract of the residual ECM . These fractions were screened
for bFGF-binding molecules by SDS-PAGE followed by li-
gand blotting (see Materials and Methods) .
Using this technique, bFGF was shown to bind to a series
of molecules ofa molecular size of ti 200kD in both the cellextract and ECM (Fig . 2, lanes 2 and 3) representing differ-
entially glycosylated variants of a proteoglycan (see below) .
In addition, a small amount of binding to species of higher
molecular weight was observed in the ECM sample and in
the medium (Fig . 2, lanes 1 and 3) . The 200-kD molecule
was spontaneously released from the cultures, since it was
also present in conditioned medium (Fig . 2, lane 1) .
The 200-kD bFGF-binding molecule was identified as a
HSPG, as it was metabolically labeled with [11S]sulfate (see
Figs . 5 and 8), and bFGF binding was abolished by pre-
treatment of the cultures with heparinase (results not
shown) . Furthermore, growth of the cells in the presence of
4-methylumberylliferyl ß-D-xyloside, which inhibits the at-
tachment of the glycosaminoglycan side chains to the core
protein of proteoglycans (Schor and Schor, 1988), almost
completely abrogatedbFGF binding to the200-kD molecule
in ligand blotting experiments (not shown) . Finally, the mol-
ecule was sensitive to proteolytic digestion, as it was re-
leased from the cultures by plasmin treatment (see Fig . 7) .
The 200-kD bFGF-binding HSPG of bone marrow cultures
was similar in size to that found in BCE cell cultures (250
kD) (Saksela and Rifkin, 1990) .
Enzymatic ReleaseofbFGFfrom
BoneMarrow Cultures
To have a biological effect in bone marrow cultures, bFGF
Figure 3 . Enzymatic release ofbFGF from bone marrow cultures .
Cells were cultured in serum-containing medium in 24-well plates
until confluent and 1 ug/ml ofrecombinantbFGF in serum-free me-
dium containing 0.15% gelatin (250 ,1/well) was added for 1 h at
37°C. After extensive washing with PBS, cells were either rinsed
briefly with serum-free medium (250,ul/well) without a further in-
cubation (lanes 1 and 4), or incubated for a further 2 h with medi-
um alone (lanes 2 and S) or 0.5 pg/ml of PI-PLC (lanes 3 and 6) .
All incubations were performed in the presence of 100 KIU/ml of
aprotinin. Aliquots (90 I1) ofconditioned media (lanes 4-6) or of
the corresponding cell lysates (lanes 1-3), prepared as described
in Fig . 1 (250,1/well), were analyzed by SDS-PAGE in a 15% gel
followed by immunoblotting as described in Fig. 1 . The last lane
contained 50 ng of recombinant bFGF.
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has to be released from its heparin-like binding sites . Since
the HSPG described above constitutes the major binding site
for bFGF in bone marrow cultures (Fig . 2 and data not
shown), the solubilization of these HSPGs might represent
a mechanism for the release of bFGF from this reservoir. It
has been shown that bFGF bound to HSPGs of the en-
dothelial cell matrix is solubilized by plasmin (Saksela and
Rifkin, 1990) or heparanases (Ishai-Michaeli et al ., 1990) .
HSPGs in liver, brain, ovaries, and lung, however, have been
proposed to be linked to the cell surface via a PI anchor
(Ishihara et al ., 1987; Carey and Evans, 1989 ; Yanagashita
and McQuillan, 1989 ; David et al., 1991) . We therefore in-
vestigated whether bFGF bound to HSPGs can be released
from bone marrow cultures by treatment with various en-
zymes .
bFGF (1 Fig/ml) was added to primary bone marrow cul-
tures for 1 h at 37°C . After extensive washing the cultures
were subsequently incubated for a further 2 h with hepa-
rinase (0.5 Ag/ml), plasmin (1 wg/ml), or PI-PLC (0.5 p,g/
ml) . bFGF release by these enzymes was demonstrated by
SDS-PAGE and immunoblotting of serum-free conditioned
media and the corresponding Triton X-100 cell lysates . After
incubation for 2 h with plasmin or heparinase, bFGF release
into the medium was slightly increased compared to control
cultures (results not shown) . In contrast, incubation of the
cultures with PI-PLC considerably increased the amount of
bFGF found in themedium as compared to the spontaneous
release ofbFGF (Fig. 3, lane 6 compared to lane S) . The re-
lease ofbFGF into the medium was associated with its cor-
responding disappearance from the cell extracts (Fig. 3, lane
3 compared to lane 2) .
To examine the time course of the release of bFGF by
PI-PLC, we incubated primary bone marrow cultures with
[ í25I]bFGF (100 ng/well ; 26,400 cpm/well) as described
above . After extensive washing, the cultures were subse-
quently incubated with PI-PLC (0.5 ug/ml) and the amount
of labeled bFGF in conditioned media, cell extracts, and re-
sidual ECM was determined at different time intervals . Ap-
proximately 66% (corresponding to 4.4 ng/well) of the cell-
boundbFGF was released byPI-PLC after incubation for 2 h
(Fig . 4) . Some of the residual bFGF contained in the cell
lysates might represent bFGF, which was internalized by the
cells during the incubation period . An initial small decrease
in the amount ofbFGF bound to the ECM was observed,
which could result from the incomplete separation of cells
and matrix as mentioned previously.
bFGFIs Released asa Complex with the200-kD
HSPG by PI-PLCandPlasmin
The highly efficient release of bFGF by PI-PLC suggested
that the major bFGF binding site, the 200-kD HSPG, might
be linked to the cell surface via a PI anchor. If this was the
case, bFGF would be solubilized by PI-PLC as a complex
with theHSPG . To test this hypothesis, we attempted to iso-
late bFGF-HSPG complexes from the supernatants of enzy-
matically treated cultures .
HSPGs of primary bone marrow cultures were metaboli-
cally labeled overnight with [11S]sulfate and incubated with
1 pg/ml of [' 251]bFGF for 1 h . After extensive washing with
PBS, the cultures were then incubated with PI-PLC, plas-
min, or heparinase to release double-labeled bFGF-HSPG
complexes . The complexes were precipitated from the super-
natants by addition of protein A-Sepharose beads coated
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Figure 4. Time course of bFGF release from bone marrow cultures
by PI-PLC. Cells were cultured in serum-containing medium in 96-
well plates until confluent and cultures were incubated with
["II]bFGF (1 pg/tnl in serum-free medium containing 0.15% gela-
tin; 264,000 cpm/ml; 100 Id/well) for 1 h at 37°C. After extensive
washing with PBS, cultures were incubated with 0.5 pg/nil of Pl-
PLC (100 td/well) containing 100 KIU/ml of aprotinin and ex-
tracted (100 ul/well) as described in Fig. 1. Radioactivity in condi-
tioned medium (e), cell extract (o), or ECM (o) was determined
by counting the samples in a gamma counter. Values represent the
mean value ofduplicate samples, and similar results were obtained
in two separate experiments.
with anti-bFGF IgG and analyzed by SDS-PAGE under
reducing conditions. This procedure separated the com-
plexes into two components-the 200-kD ["S]HSPG and
the 18ÁD ['z5I]bFGF. Supernatants of cultures incubated
with PI-PLC contained considerably higher amounts of
bFGF-HSPG complexes than the medium control (Fig. 5 A,
lane 5 compared to lane 2). This is in agreement with the
increased release of bFGF by PI-PLC shown in Fig. 3.
Whereas plasmin also released an increased amount of
bFGF-HSPG complexes compared to control cultures (Fig.
5, lane 4 compared to lane 2), heparinase did not signifi-
cantlyalterthe amount ofbFGF released spontaneously from
thecultures (Fig. 5, lane 3compared to lane 2). The presence
ofboth bFGF and HSPG in the precipitates indicated the re-
lease of intact bFGF-HSPG complexes from bone marrow
cultures by treatment with PI-PLC and, to a lesser extent,
by plasmin. The amount of bFGF released under the differ-
ent conditions used was quantitated by densitometric scan-
ning of the bFGF band (Fig. 5 C). The results indicated that
PI-PLC and plasmin were more effective in releasing bFGF
than heparinase.
Using the same technique, we isolated bFGF-HSPG com-
plexes released from BAE and BCE cell cultures by PI-PLC
treatment. The bFGF-binding HSPGs of these cultures
differed somewhat in their molecular size from those of bone
marrow cultures (Fig. 5 B and Saksela and Rifkin, 1990) .
It appeared, however, that the spontaneous release of bFGF
was not significantly increased by incubation with PI-PLC
(Fig. 5, lanes 2 and 4 compared to control lanes 1 and 3) .
This conclusion was also supported by the densitometric
scanning of the bFGF band (Fig. 5 C) . A band of increased
intensity was observed at the top ofthe gel after addition of
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PI-PLC to BAE cells (Fig. 5 B, lane 2). This was not repro-
ducible and most likely comprised aggregates of proteogly-
cans which were unable to enter the gel.
These results suggest the existence of different types of
bFGF-binding HSPGs in primary human bone marrow cul-
tures and in bovine endothelial cell lines which differ in their
sensitivity towards release by PI-PLC.
TheReleased bFGF-HSPG Complex
IsBiologicallyActive
bFGF is known to stimulate PA production in endothelial
cells (Moscatelli et al ., 1986; Presta et al., 1986) and, as
mentioned previously, bFGF complexed to HSPGs is most
likely the biologically active form of this growth factor. To
determine whether the bFGF, which is released as a complex
with the 200-kD HSPG (see Fig. 5 A), is biologically active,
we incubated BAE cells overnight with bFGF-HSPG com-
plexes that had been released from bone marrow cultures af-
ter incubation with PI-PLC. The cells were then lysed in Tri-
ton X-100, and the PA activity in the lysates was determined
using plasminogen and DVal-Leu-Lys p-nitroanilide as sub-
strates.
bFGF (1 and 3 ng/ml) increased PA production by BAE
cells 2-2 .3-fold (Fig. 6, columns 2 and 3 compared to
column 1). bFGF-HSPG complexes, released from bone
marrow cultures by treatment with PI-PLC, stimulated PA
production 3.3-fold at a dilution of 1:250 (Fig. 6, column 8
comparedto column 1) and2.4-foldat 1:1,250 (Fig. 6, column
9 compared to column 1). At these dilutions, control condi-
tioned medium as well as PI-PLC itself (0.5 ug/ml) did not
affect PA activity (Fig. 6, columns 4 and S compared to
column 1, and results not shown) . These results indicate that
the amount of bFGF released by PI-PLC exceeded 1 ug/ml
and was significantly higher than that released spontaneously
from the cultures. To exclude the possibility that the stimula-
tion of PA production was caused by other compounds re-
leased from the bone marrow cells, we attempted to reverse
the stimulatory effect by inhibitory antibodies to bFGF The
basal PA activity of BAE cells was almost completely sup-
pressed by anti-bFGF antiserum (Fig. 6, columns 6 and 7
compared to 4 and 5). Apparently the basal PA activity ob-
served was due to the endogenous release of bovine bFGF-
HSPG complexes (see Fig. 5 B). Similarly, the PA activity
of BAE cells stimulated by the PI-PLC releasates from the
bone marrow cultures was almost completely suppressed by
anti-bFGF antiserum (Fig. 6, columns 10 and Il compared
to columns 8 and 9). These results indicated the presence
of active bFGF in the conditioned media. PA induction due
to the release ofendogenous bovine bFGF-HSPG complexes
catalyzed by the PI-PLC contained in the stromal cell condi-
tioned media can be excluded, since a concentration of PI-
PLC 1,000-fold higher than used in these experiments did
not release detectable amounts of bFGF from endothelial
cells after an incubation period of 2 h (Fig. 5 B).
The200-kD HSPGIsLinked to the CellSurface
viaa PIAnchor
The release of the bFGF-HSPG complexes from primary
bone marrow cultures by PI-PLC (see Fig. 5 A), but not by
phosphatidylcholine-specific PLC (results not shown), indi-
cated the presence of a PI-containing cell surface anchor for
the 200-kD bFGF-binding HSPG. One would therefore ex-Figure 5 . Demonstration of enzymatically released bFGF-HSPGcomplexes. Cells were cultured in serum-containing medium in 24-well
plates until confluent and proteoglycans were metabolically labeled overnight with [35S]sulfate (40 jkCi/ml in serum-free medium; 250
Al/well) . ['z5I]bFGF (1 ug/ml in serum-free medium containing 0.15% gelatin; 100,000 cpm/ml ; 250,u1/well) was then added to the cul-
tures for 1hat 37°C . (A)Bone marrow cultures . After extensive washing with PBS, double-labeled bFGF-HSPGcomplexeswere released
by incubation for 2 h at 37°C with medium alone (250 j1/well) (lane 2), 0.5 pg/ml of heparinase (lane 3), 1 ug/ml of plasmin (lane 4),
or0.5 Ag/ml of PI-PLC (lane 5) . All incubations, except for those containing plasmin, were performed in the presence of 100 KIU/ml
ofaprotinin. Thecomplexes were then isolated by precipitation with protein A-Sepharose beads coated with anti-bFGF IgG, andanalyzed
by SDS-PAGE in 3-16% gel gradients followed by autoradiography. Lane 1 contained 0.2 ng (3,500 cpm) of ['z5I]bFGF. No labeled pro-
teins were precipitated using protein A-Sepharose beads coated with normal rabbit IgG (not shown) . (B) Endothelial cell cultures . Incuba-
tion ofBAE cells with medium alone (lane 1) or PI-PLC (lane 2) . Incubation ofBCE cells with medium alone (lane 3) or PI-PLC (lane
4) . (C) The intensity ofthe [125I]bFGF band wasdetermined by scanning ofthe autoradiograph . Thepeak area of the scans wasexpressed
in relative units and is shown below the corresponding lanes.
pect that the HSPG itself should be released by PI-PLC .
Moreover, the HSPG should be metabolically labeled with
PI anchor components, such as ethanolamine and fatty acids.
To test the first assumption, primarybone marrow cultures
were incubated at 37°C with medium, plasmin, or PI-PLC,
and after varioustime intervalsthe resulting conditioned me-
dium as well as thecorresponding cell extracts were analyzed
by bFGF ligand blotting . All incubations, except for those
containing plasmin, were performed in the presence of 100
KIU/ml of aprotinin. The bone marrow cultures spontane-
ously released trace amounts of the 200-kD bFGF-binding
HSPG into the medium (Fig . 7 A, lanes 1-4) . Incubation of
the cell layer with 1 pg/ml of plasmin for 2 h resulted in a
significant increase in the release of the200-kD HSPG (Fig.
7, lane 8compared to 4) . In contrast, PI-PLC (0.5 ug/ml)
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solubilized considerable amountsofthe 200-kD HSPG after
3-10 min (Fig . 7, lanes 9and 10 compared to control lanes
1 and 2 and plasmin lanes 5 and 6), and the release was
almost complete after 2 h (Fig. 7, lane 12) . The release of
the 200-kD HSPG into the medium was associated with a
marked reduction in the corresponding cell-associated HSPG
(Fig . 7 B) .
To determine thepercentage of the total proteoglycan that
was released by PI-PLC, we labeled primary bone marrow
cultures overnight with ["S]sulfate. Cultures were then in-
cubated with PI-PLC and the radioactivity in the superna-
tant,,cell extracts and residual ECM was determined at
different time intervals. Aftera 2 h incubation with PI-PLC,
a period which permitted almost complete release of the
200-kD bFGF-binding HSPG (see Fig. 7, lane 12), -40%
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Figure 6. PA induction in BAE cells by bone marrow-derived
bFGF-HSPG complexes. Bone marrow cultures were preincubated
with 10 ug/ml ofbFGF in serum-free BAE medium containing
0.15% gelatin, and bFGF-HSPG complexes were released by incu-
bation with medium alone (columns 4-7) or PI-PLC (columns
8-11) as described in Fig . 5. Aliquots (100 11) ofserum-free control
medium (columns 1-3) or of diluted bone marrow culture condi-
tioned media (columns 4-11) were added to confluent BAE mono-
layers seeded in 96-well plates and incubated overnight at 37°C . PA
activity in BAE cell lysates was then assayed for 30 min at 37°C
as described in Materials and Methods and expressed as the mean
value oftriplicate wells f SEM . Control medium (column 1) ; me-
dium containing 1 (column 2) or 3 ng/ml (column 3) of recombi-
nantbFGF ; bone marrow culture conditioned media diluted 1:250
(columns 4 and 6) or 1:1,250 (columns 5 and 7) ; PI-PLC-condi-
tioned mediadiluted 1:250 (columns 8and 10) or 1:1,250 (columns
9 and 11) . Conditioned media contained either anti-bFGF anti-
serum 1 :50 (columns 6, 7,10,11) or preimmune rabbit serum 1:50
(columns 4, 5, 8, 9) .
of the total cellular [35S]sulfate label was solubilized . This
appeared to be derived predominantly from the cells, as
there was little change in the ["S]sulfate content of the ma-
trix (results not shown) .
To test the second assumption, namely that the 200-kD
HSPG is linked to the cell surface via a PI anchor, primary
bone marrow cells were metabolically labeled overnight
with 167 pCi/ml of [3H]ethanolamine, with 0.8 mCi/ml of
a [3H]palmitic acid-BSA complex, or with 40 ACi/ml of
["S]sulfate. bFGF-binding molecules were isolated from
cell lysates by the addition of protein A-Sepharose coated
withbFGF-anti-bFGF IgG complexes . The precipitates were
analyzed by SDS-PAGE followed by autoradiography. The
200-kD HSPG labeled by ethanolamine (Fig. 8, lane 2), by
palmitic acid (lane 2), or by sulfate (lane 3) was precipitated
by this technique . Incubation of the precipitated [3H]pal-
mitate-labeled HSPG with 3.3 ug/ml of PI-PLC for 2 h at
37°C resulted in a significant removal of the label as com-
pared to incubation with medium alone (results not shown) .
This indicated that part of the fatty acid was incorporated
into the PI anchor. The HSPG was not precipitated by addi-
tion of protein A-Sepharose beads coated with preimmune
rabbit IgG (not shown) . Bonemarrow cells were noted to ex-
press two or three other bFGF-binding proteins that were la-
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Figure 7 . Time course ofHSPG release from bone marrow cultures
by PI-PLC or plasmin . Experimental conditions were as described
in Fig . 3 . The medium control and the PI-PLC incubation mixture
contained 100 KIU/ml of aprotinin . Cells were incubated with
medium alone (lanes 1-4), plasmin (lanes 5-8), or PI-PLC (lanes
9-12) for 3 min (lanes 1, 5, 9), 10 min (lanes 2, 6, 10), 30 min
(lanes 3, 7,11), or 120 min (lanes 4, 8,12) . Serum-free conditioned
media (A) and the corresponding cell lysates (B) were analyzed by
bFGF ligand blotting as described in Fig . 2 .
beled by palmitic acid as these were also specifically precipi-
tated withbFGF and anti-bFGF IgG (lane 2) . This might be
due to the limited specificity ofthe metabolic labeling using
fatty acids, since they have been found to be covalently at-
tached to proteins by direct acylation (Schmidt, 1989) or to
be converted to amino acids.
The release of the 200-kD HSPG by low concentrations
ofPI-PLC, as well as the presence of ethanolamine and a PI-
PLC-removable fatty acid, indicate cell surface linkage of
this molecule via a PI anchor .
Discussion
The multifunctional, autocrine growth factor, bFGF, is
known to be a potent mitogen for human bonemarrow stro-
mal cells (Oliver et al ., 1990) and also stimulates myelopoi-
esis in long-term human bone marrow cultures (Wilson et
al ., 1991) . In this report, we have shown that bFGF can be
extracted from the ECM of primary human bone marrow
cultures, as has been demonstrated for endothelial cell-de-
rived ECM (Vlodavsky et al ., 1987) . This suggests that
bFGF is produced by human bone marrow cells and that it
is subsequently deposited into the stromal cell matrix . WeFigure 8 . Metabolic labeling ofthe PI anchor ofthe 200413HSPG .
Cells were incubated overnight with 167 /ACi/ml of [3H]ethanol-
amine (lane 1), 0.8 mCi/ml of a [3H]palmitic acid-BSA complex
(lane 2), or with 40 ACi/ml of [35S]sulfate (lane 3) (see Materials
and Methods) . Cell extracts were prepared as described in Fig . 1 .
and bFGF-binding HSPGs were isolated by addition of protein
A-Sepharose coatedwithbFGF-anti-bFGFIgGcomplexes . Precipi-
tates were analyzed bySDS-PAGE followed by autoradiography as
described in Fig . 5 . Addition of protein A-Sepharose beads coated
with preimmune rabbit IgG did not precipitate any of these bands
(not shown) . The results of two separate labeling experiments are
shown .
were, however, unable to detect significant amounts ofbFGF
in Triton X-100 cell lysates of bonemarrow cells . This could
be explained by the observation that the bFGF released dur-
ing cell lysis is absorbed by theECM (Gajdusek and Carbon,
1989) . An alternative explanation is the limited sensitivity
ofthe immunoblotting technique. Thus, the concentration of
bFGF in cell lysates might have been too low to be detected,
whereas continuous bFGF deposition in the ECM probably
led to the enrichment of the growth factor in the matrix .
Primary bone marrow cultures had a high capacity for
binding bFGF (>70 ng/105 cells), and their binding sites
were not saturable by concentrations as high as 1 jig/ml of
growth factor. More than 95% of the bFGF binding sites in
bone marrow cultures were heparin-like in nature, which is
consistent with earlier results obtained with BCE cells,
which express >101 heparin-like bFGF binding sites per
cell compared to only 6,000-17,000 high affinity bFGF re-
ceptors per cell (Moscatelli, 1987, 1988) .
The major bFGF binding protein in primaryhuman bone
marrow cultures was characterized as a cellular HSPG with
a molecular size of ti200kD. This species was found in cell
lysates and in conditioned media . The size of this bFGF-
binding HSPG is similar to one of the bFGF-binding HSPGs
of BCE cells identified previously (Saksela and Rifkin,
1990), which had a molecular mass of ti250 kD. Both
proteoglycans were found in cell lysates and conditioned
medium .
bFGF was very efficiently released from its binding sites
inhuman bonemarrow cultures by incubation with PI-PLC .
Equimolar amounts of plasmin and heparinase were either
less efficient or unable to solubilize significant amounts of
bFGF in this system . However, it should be noted that the
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catalytic efficiencies of the different enzyme preparations
were unknown . The bFGF was solubilized by PI-PLC as a
complex with the200-kD HSPG, since both molecules were
coprecipitated with anti-bFGF IgG . This complex exhibited
biological activity as it stimulated PA production in BAE
cells, supporting the hypothesis thatbFGF-HSPG complexes
are biologically active and relevant . In fact, Yayon et al .
(1991) have recently shown that heparin-like molecules are
essential for the binding ofbFGF to its high affinity receptor.
Essentially complete release of the major bFGF-binding
molecule, the 200-kD HSPG (constituting -40% ofthe total
cellular proteoglycan), was observed after exposure to PI-
PLC . Plasmin was less effective in solubilizing the 200-kD
HSPG. The solubilization of the 200-kD HSPG by PI-PLC
indicated a linkage of this proteoglycan to the cell surface via
a PI anchor. This was confirmed by the metabolic labeling
of the HSPG with ['H]ethanolamine or [ 3H]pahnitic acid .
The fatty acid label could be partially removed by treatment
of the HSPG with PI-PLC, indicating incorporation of the
fatty acid in the PI anchor. PI-linked HSPGs have been de-
scribed for several other cell types, hepatocytes (Ishihara et
al ., 1987), Schwann cells (Carey and Evans, 1989), ovarian
granulosa cells (Yanagashita and McQuillan, 1989), and
lung fibroblasts (David et al ., 1990) . In contrast, a sig-
nificant release by PI-PLC of the bFGF-binding HSPGs of
BAE and BCE cells could not be detected under the condi-
tions used . However, since the experiments with the bone
marrow cultures were performed with primaryhuman cells,
while the experiments with the bovine endothelial cells were
not, the presence ofPI-linkedHSPGs on primaryhuman en-
dothelial cells can not be excluded . In addition, the PI an-
chors in different PI-linked proteins vary in their structure
and not all of these molecules can be released by PI-PLC
(Low, 1989) .
Despite the large variety of proteins found to be linked to
the cell surface via PI anchors (Low, 1989), the biological
significance of this anchor and the mechanism ofits cleavage
in vivo are not yet understood . In the instance of the200-kD
bFGF-binding HSPG of human bone marrow cultures, the
PI linkage might provide a highly selective and efficient
mechanism for releasing active growth factor without any
additional perturbation of the microenvironment . Further-
more, the biologically active bFGF-HSPG complex, to-
gether with other PI-linked molecules on the stromal cell
surface, might comprise a group of factors, which can
cooperate in supporting haematopoiesis and which can be
made available by the action of a single specific enzyme .
While a constitutive secretion or shedding of the 200-kD
HSPG from the bone marrow cultures can not be excluded,
its spontaneous release even in the presence of the plasmin
inhibitor aprotinin might indicate the presence of an endoge-
nous anchor-specific phospholipase in these cultures .
This novel mechanism of the phospholipase-catalyzed re-
lease of activebFGF in human bone marrow cultures might
result in the specific and sensitive regulation of the hemato-
poietic process in vivo. A cell surface-bound PI-PLC has re-
cently been detected on Swiss 3T3 fibroblasts (Ting and
Pagano, 1990), and anchor-specific phospholipase Ds have
been identified and purified from human plasma and bovine
brain (Davitz et al ., 1989 ; Hoener et al., 1990) . Moreover,
an anchor-specific phospholipase D has been demonstrated
inhuman mast cells, a cell type which originates in the bone
1282marrow (Gleichauf, C., P. Thomas, and M. A. Davitz. 1990.
J. Cell Biol. 111:1098). However, an enzyme that might be
capable of catalyzing the release ofbFGF-HSPG complexes
in human bone marrow has not yet been identified.
In conclusion, bFGF deposition in the microenvironment
ofbone marrow stromal cells and its release in a biologically
active form either by a specific phospholipase or by the initi-
ation of the proteolytic cascade of plasminogen activation,
might constitute important events in cell-cell interactions of
stromal and progenitor cells during haematopoiesis.
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